Selecta to receive $10M up front, ~$340M in additional development and commercial milestones along with royalties on commercial sales. Xork used as a pre-treatment for AT845
Selecta will lead the development & manufacturing of Xork and will have the rights for the development of additional indications beyond Pompe disease. Astellas get an exclusive commercialization right for Pompe disease & can combine Xork with an Astellas gene therapy product AT845
The agreement enables Astellas to advance its gene therapy portfolio & also helps to deliver transformative gene therapy treatments to LOPD patients who may not be eligible for clinical trials or treatment with Astellas’ AT845
Ref: PRNewswire | Image: Astellas
Related News:- Astellas Reports the US FDA’s Clinical Hold on the P-I/II (FORTIS) Trial of AT845 for the Treatment of Adults with Late-Onset Pompe Disease
